FOS and breast cancer: c-Fos is induced by 17β-estradiol (E2) via a SRE-dependent manner in human uterine endometrial cancer (HEC) or breast cancer cell lines [65–67], while HOPX could act as a tumor suppressor by regulating the SRF-c-fos-cyclin D1 pathway in HEC [12].